Date: 2012-09-04
Type of information: Fundraising
Company: Laurantis Pharma (Finland)
Investors: Broadview Ventures (USA) - Inveni Capital - Aloitusrahasto Vera - Helsinki University Funds (Finland) - Veritas
Amount: € 5.64 million
Funding type:
Planned used: The funding will support the first human trial for Lymfactin®, which has potential to become the first treatment for breast cancer-associated lymphedema. Lymfactin® uses an adenoviral vector to deliver vascular endothelial growth factor (VEGF-C) during transplantation of lymph nodes in order to avoid lymphedema.
Others: Laurantis Pharma has announced successful completion of a funding round, which raised € 5.64 million (US$7.02 million). A significant amount of the financing was secured from Broadview Ventures, Inc., which served as a catalyst for raising funds from Inveni Capital, Aloitusrahasto Vera, Helsinki University Funds, and Veritas.
Based in Turku, Finland, Laurantis is a privately held clinical-stage biotechnology company with a broad portfolio of first-in-class products based on two proprietary technologies. The Company\'s pipeline includes proprietary and patent-protected formulations and applications of cis-urocanic acid, a locally acting anti-inflammatory and anti-proliferative agent for the treatment of Atopic Dermatitis, Dry Eye, Interstitial Cystitis, and Bladder Cancer. Laurantis is also developing Lymfactin®, a vascular endothelial growth factor C (VEGF-C) in an adenoviral vector, for the treatment of secondary lymphedema.
Therapeutic area: Immunological diseases - Inflammatory diseases
